Corvus Pharma

Forecast & Rating8 analysts currently cover Corvus Pharma, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $33.14, about 124.4% upside from the current price of $14.77. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 80.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Corvus Pharma closely still see room for the stock to rise. Data as of Aug 12, 2026; for reference only and not investment advice.